Read success stories about startup companies that license technology from the University of Florida. Over the past decade, the Office of Technology Licensing has launched more than 100 companies. These startups are developing products that cure diseases, create jobs, and help make the world a better place.
Two UF startups, AxoGen and Sentinel Diagnostic Imaging, are among 20 outstanding companies chosen from a record number of applicants to present to investors and corporations seeking acquisition at the 2014 Southeastern Medical Device Association (SEMDA) Conference, Thriving During Healthcare Reform.
Local startup TruVitals developed a wireless vital signs monitor. Commercialized as the TruVitalPet, the monitor tracks any animal’s vital signs without making physical contact.
The biotech startup AxoGen opened a distribution center in Burleson, Tex., this month. Based in Alachua, the company also has facilities in Virginia Beach, Va. AxoGen's products repair damaged peripheral nerves.
eTect announced today it has been authorized to move ahead on the second phase of its Fast Track SBIR grant by the National Institute on Drug Abuse (NIDA). Phase 2 of the NIDA program will provide $1,000,000 of research support for product development and clinical testing of the ID-Cap system.The ID-Cap is a standard HPMC or gelatin capsule embedded with a wireless sensor that verifies the ingestion of medication in real time. As the patient ingests the ID-Cap, the sensor draws power from the stomach acids and uses a two-way communication system to confirm the ingestion of the medication.
It's not uncommon to find John McGuire and his team at Rapid Genomics criss-crossing the world, touting the latest methods in DNA genotyping. The story behind Rapid Genomics, which had $2.7 million in net income in its first 1 1/2 years, begins several years ago UF when a group of scientists launched an investigation into a method of genotyping that could sequence genomes more quickly by amplifying and targeting specific molecular strands. McGuire visited the Innovation Hub in 2012 and saw potential in the early research being done by Matias Kirst and his colleagues.
Optym, a Gainesville software company, will add 100 jobs and invest $4.8 million in capital as part of its expansion plans. Optym, which recently changed its name from Innovative Scheduling, was founded in 2000 and has about 100 employees spread over its Gainesville headquarters, a software development office in Armenia and a data analysis office that opened last year in India.
Optym, Formerly Innovative Scheduling, Expands Gainesville Operations, Creating 100 Jobs (Chamber of Commerce)
Optym, formerly Innovative Scheduling, a leading developer of planning and scheduling software for the transportation and logistics industry, will expand its operations in Gainesville, creating 100 new jobs and a spurring a capital investment of nearly $5 million in the area. Optym was founded in 2000 by UF professor Dr. Ravindra K. Ahuja.
Applied Genetic Technologies Corp. (AGTC), a gene therapy company based on UF technology, raised $50 million through an initial public offering on March 27 after offering nearly 4.2 million shares at $12 each. The company is trading on the Nasdaq Global Market under the symbol AGTC and this IPO is the second largest in the area. AGTC develops cures for rare lung and eye diseases by replacing broken genes with normally functioning genes.
Paracosm working with Google on Project Tango to bring 3-D to the hands of consumers (Gainesville Sun)
Paracosm, the developers of 3D model software licensed from the University of Florida, has been working with Google on “Project Tango” for several months. Project Tango is a collaborative effort to bring 3D mapping to the hands of the average consumer. Paracosm formally announced their partnership and showed this new application of their 3D modeling software.
The Cade Museum announced the Sweet 16 finalists for the $50,000 Annual Cade Museum Prize. This award is given to a Florida individual or company that is taking an original idea or product to market. The three finalists taking University of Florida technologies to market are: Advanced Technologies & Testing Laboratories, Transformair – Eliminates airborne bacteria, viruses, allergens, mold and volatile organic compounds; Paracosm, Reality API – Software that helps businesses build 3D maps of their facilities; and Quick-Med Technologies, Stay Fresh – An antimicrobial coating based on hydrogen
HyGreen, Inc. today announced a collaborative partnership with The Ministry of Health (MoH) of the Kingdom of Saudi Arabia. The HyGreen Hand Hygiene Reminding and Recording System will be deployed in 25 MoH hospitals supporting its goal of reducing hospital acquired infections through improved hand hygiene. Developed at the University of Florida, Hygreen is an electronic hand hygiene monitoring system that not only records all hand hygiene events in the hospital, but reminds busy healthcare workers to wash their hands between patients.
The ViewRay system is the world’s first and only MRI-guided radiation therapy system. ViewRay announced the system is being used to treat patients at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO. Spun out of University of Florida research, ViewRay Inc. is a privately held medical company developing advanced radiation therapy technology for the treatment of cancer.
Shadow Health has become the first company to receive equity financing from the Florida Institute for the Commercialization of Public Research. The deal between Shadow Health and the Florida Institute gives Shadow $200,000 in equity funding. Shadow Health is developing interactive learning environments for nursing and allied health education programs and licensing part of its technology from the University of Florida.
Banyan Biomarkers, Inc., a biomedical company developing a first of its kind point-of-care blood test to rapidly detect the presence of mild and moderate brain trauma, is one of sixteen winners of the $20M Head Health Challenge. The Head Health Challenge is sponsored by the National Football League and General Electric to improve the health of athletes, members of the military and society overall. Banyan Biomarkers’ researchers will work with the University of Florida on a sports concussion research study to analyze biomarkers, neurocognitive testing and neuroimaging on athletes with concussi
Applied Genetic Technologies, a clinical-stage biotech developing treatments based on University of Florida research for orphan eye diseases, filed on Friday with the SEC to raise up to $70 million in an initial public offering. The Alachua, FL-based company plans to list on the NASDAQ under the symbol AGTC.
Navy Corpsman Edward Bonfiglio and Axogen ‘s Jill Schiaparelli on Fox & Friends and Rose Parade (Fox News)
Navy Corpsman and Purple Heart recipient Edward Bonfiglio and Senior Vice President of Axogen, Inc. (NASDAQ: AXGN) Jill Schiaparelli were featured on Fox & Friends with Anna Kooiman. Bonfiglio rode atop the Donate Life float as the first nerve tissue recipient to be honored in the Rose Parade. While in Afghanistan, Bonfiglio sustained a sciatic nerve injury which was repaired using Axogen’s Avance® Nerve Graft. Bonfiglio and Schiaparelli share the story of his injury and how the Avance® Nerve Graft saved Bonfiglio’s leg from amputation.
TapShield has raised $750 thousand in financing, including private investment which matched public funding from the Florida Institute for the Commercialization of Public Research. Led by former University of Florida Student Body President, Jordan Johnson, TapShield is a security company using UF research to develop a mobile inbound emergency alert system that allows users to send a detailed report to police dispatch via a smartphone application.
AGTC, a privately-held, clinical stage biotechnology company founded with research from the University of Florida, announced that the company has been awarded an additional $657,699 in funding under the Small Business Technology Transfer Program of the National Eye Institute. This grant will supplement ongoing work under the $8.4 million grant AGTC was awarded by the NEI earlier in 2013 and support expansion of the company’s preclinical development work.
ViewRay Closes $30M Financing to Expedite Commercialization of its MRI-Guided Radiation Therapy System
ViewRay Incorporated has secured another $30 million in funding from existing equity investors, as well as debt financing. The funds are to support commercialization of the ViewRay system, which has already been acquired by five leading cancer treatment centers worldwide. Developed by University of Florida researcher and Chief Technology Officer James F. Dempsey, Ph.D., the ViewRay system is designed to improve the accuracy of cancer treatments through a patented combination of simultaneous Magnetic Resonance Imaging (MRI) and radiation therapy delivery.
Space Florida and UCF announced the finalists for the 2014 CAT5 Awards. Several companies pitching for a portion of the $150,000 prize are formed around University of Florida research, including: • NanoPhotonica (Orlando, FL) – materials for flat panel displays and other solid state lighting applications • ReliOx Corporation (Gainesville, FL) – environmentally safe antimicrobial and disinfectant products • TruVitals, Inc. (Gainesville, FL) – a non-invasive medical vital signs monitoring system. Also invited to pitch: • Paracosm (Gainesville, FL) – 3D modeling of building structures and
AxoGen, Inc. (NASDAQ: AXGN) is moving forward with plans to open a distribution center in Texas to add same-day shipping of its surgical products to the West Coast. The company currently has 65 employees and will continue to hire in Alachua, FL and Burleson, TX. AxoGen, Inc. is a pioneer in peripheral nerve reconstruction and regeneration solutions, using research from the University of Florida to provide surgeons with solutions to repair and protect peripheral nerves.
AGTC Scientific Founders William W. Hauswirth and R. Jude Samulski Receive Pioneer Awards for Seminal Work in Gene and Cell Therapy
Applied Genetic Technologies Corporation (AGTC) announced that two of the company’s scientific founders, William W. Hauswirth, Ph.d., University of Florida College of Medicine, and R. Jude Samulski, Ph.D., Gene Therapy Center, University of North Carolina at Chapel Hill, have been named Pioneer Award winners by peer-reviewed journal Human Gene Therapy, for their seminal work in gene and cell therapy. AGTC is a clinical stage biotechnology company developing adeno-associated virus (AAV)-based systems, as a result of University of Florida research, to deliver human therapeutics.
The latest Issue of Florida High Tech is devoted to Innovation. Several University of Florida inventors and companies developed around UF technologies are featured, including: • Raghavan “Charu” Charudattan, Ph.D. – BioProdex, Inc. • Martin Handfield, Ph.D. – Oragenics Inc. • Matias Kirst, Ph.D. – RAPiD Genomics • Benjamin Lok, Ph.D. – Shadow Health • David E. Richardson, Ph.D. – ReliOx Corporation • Gerry Shaw, Ph.D. – EnCor Biotechnology Inc. • Hari Thrivikramji, M.D. – Enterade USA LLC
Paracosm Receives Seed Funding for 3-D Modeling and Navigation Software from the Florida Institute (Miami Herald)
The Institute for the Commercialization of Public Research announced that it has finalized a funding agreement with Paracosm, developers of indoor 3-D modeling and navigation software. Paracosm is using technology developed at the University of Florida to leverage advances in computer-aided design (CAD) to convert consumer-grade depth cameras into powerful 3-D mapping systems.
AGTC reported encouraging results from a phase II clinical trial using its proprietary AAV gene therapy vector system developed at the University of Florida. Data from the study with the University of Massachusetts Medical School demonstrate that intramuscular administration of AAV-based therapies supports sustained expression of a therapeutic protein for up to a year following a single dose. AGTC is a clinical stage biotechnology company developing adeno-asssociated virus (AAV)-based systems to deliver human therapeutics.
AxoGen, Inc. (NASDAQ: AXGN) CEO Karen Zadarej sits down with Pimm Fox on Bloomberg Television’s “Taking Stock.” She speaks to the new tax on medical devices and its effects on small companies. AxoGen, Inc. is a pioneer in peripheral nerve reconstruction and regenerations solutions, using research from the University of Florida to provide surgeons with solutions to repair and protect peripheral nerves.
NanoPhotonica is developing a brighter, greener, less-expensive screen-lighting system for smartphone and tablet display screens. This University of Florida technology has attracted the attention of manufacturing partners in Japan, Taiwan, and South Korea, as well as millions of dollars from private investors and public grant agencies in Florida.
AxoGen Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500 (AxoGen press release)
AxoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, announced it ranked 19th on Deloitte’s Technology Fast 500™, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America.
The winner of the 2013 BIO/Plan Competition is Constellation Research, which was created with technology developed at the University of Florida and is based in the Florida Innovation Hub in Gainesville. The company is developing clinical diagnostic tools to help prevent and end blindness caused by diabetic retinopathy and macular degeneration. It is currently developing a software platform to enable comprehensive and reproducible assessment of imaging features in the retina in order to improve eye care and disease management in diabetic patients. The company is raising $1.5 million to prepare
Prioria Robotics has been awarded $4.5 million worth of contracts to produce 36 small unmanned aircrafts and 12 ground control stations for the U.S. Army. Each Maveric Unmanned Aircraft System consists of three hand-launched aircrafts, a ground control station and various payloads that include equipment for intelligence gathering, surveillance and reconnaissance, CEO Bryan da Frota said.
Think of it as LinkedIn for kids. A new website, ethosU.com, is for kids from kindergarten on up. It’s a reputation-building site, designed to help parents build positive profiles of their children online. The social networking site is a partnership between a Naples, Fla., entrepreneur and a University of Florida professor who developed the technology behind it, which includes the ethosU Reputation Quotient, or eRQ. The higher the eRQ, the better for the student — the sky is the limit, there’s no cap.
The city of Alachua's past, present and future were on display Wednesday morning as Nanotherapeutics broke ground on a 165,000-square-foot facility on the grounds of the former Copeland Sausage plant. During a ceremony under a big tent with Gov. Rick Scott and about 250 people in attendance, Mayor Gib Coerper recalled that the plant's closing devastated the town in 1976. That was before the University of Florida's nearby Sid Martin Biotechnology Incubator started nurturing companies built from medical research that fill the surrounding Progress Corporate Park.
Nanotherapeutics Breaks Ground on Advanced Development and Manufacturing Center in Alachua (Business Wire)
Nanotherapeutics, Inc. broke ground on its Advanced Development and Manufacturing Center (NANO-ADM) in Copeland Park, Alachua. The groundbreaking ceremony, hosted by Tim Giuliani, President of the Gainesville Area Chamber of Commerce, featured speakers including Governor Rick Scott, The Honorable Gib Coerper, Mayor of the City of Alachua, and James Talton, Ph.D., Co-founder, President and Chief Executive Officer of Nanotherapeutics. The 30-acre NANO-ADM Center, constructed through privately secured financing fulfills the contract awarded to Nanotherapeutics by the U.S. Department of Defense ea
A pharmaceutical company that earlier this year spun out of a University of Florida research lab has now secured a $32 million venture capital investment to go with an agreement that could be worth up to $300 million to sell to a major multinational pharmaceutical company. Sideris Pharmaceuticals announced the financing deal Tuesday. It was led by MPM Capital, a $2.6 billion venture firm based in Boston, with additional funding from Hatteras Venture Partners and Osage University Partners. As part of the financing, Sideris also has an agreement granting exclusive rights to Novartis Pharmaceutic
Oragenics, an oral-care probiotics company based on technology developed at UF, has signed an exclusive channel collaboration agreement with Intrexon, a biotechnology company, to develop and commercialize genetically modified probiotics for the treatment of diseases of the oral cavity, throat, sinus and esophagus.
Xhale Assurance, Inc., developer of the unique Assurance® Alar One-Sense™ Pulse Oximetry Sensor, announced that its new Alar One-Sense™ Sensor will be highlighted in three clinical research presentations at the American Society of Anesthesiologists (ASA) annual meeting in San Francisco, October 12-14. The ASA conference, ANESTHESIOLOGY™ 2013, is the most comprehensive anesthesia-related educational event in the world, with 10,000 anesthesiologists expected to attend.
Alachua-based Banyan Biomarkers received a $13 million Department of Defense contract to adapt its blood test that diagnoses traumatic brain injury to work with a lab test device made by Ortho Clinical Diagnostics, a subsidiary of Johnson & Johnson. OCD's' Vitros MicroWell device will be used to analyze clinical trial samples.
UF startup AGTC and the university's ophthalmology department received an $8.4 million grant from the National Eye Institute at the National Institutes of Health to study gene therapy for achromatopsia, a genetic condition that severely impairs vision. The NEI gives out few grants each year, and this one lasts five years. “It’s a very significant grant. It’s a great validation of the team that we put together,” said Sue Washer, president and CEO of AGTC.
When Rick Carlson returned to Gainesville in December 2011 to raise his son near his in-laws, he had no idea he would be starting his software company in such a supportive environment for tech startups. Carlson is founder and president of SharpSpring, a startup company based on technology developed at UF that provides software for small businesses to generate and track sales leads.
Jonesville-based eTect received a $1.2 million Small Business Innovation Research grant from the National Institute on Drug Abuse to develop pills with tiny sensors that, when taken, send a signal to a monitor worn by the patient. eTect president Eric Buffkin said the NIDA is interested in the technology to track patient adherence to treatments for drug addiction. The sensors, developed by Convergent Engineering and the UF College of Engineering, include microchips the size of a grain of sand.
Forget chemicals or pills in the fight against nasty bacterial infections. Entrepreneur Mark Spiecker is betting that the secret lies with sharks. Those fast and carnivorous fish just happen to have microscopic textures on their skin that make them highly resistant to barnacles, algae and, surprisingly, most human bacteria. Spiecker is CEO of a six-year-old company called Sharklet Technologies that has copied those mathematical patterns to create germ-deflecting surfaces for everything from medical devices to computer keyboards.
Axogen, Inc. produced a compelling video about how a UF nerve-graft technology has helped to save soldiers' limbs from amputation.
Nanotherapeutics Awarded Defense Department Contract for Advanced Development and Manufacturing of Medical Countermeasures
Nanotherapeutics, Inc., announced it has been awarded a Department of Defense contract to establish Medical Countermeasures Advanced Development and Manufacturing (MCM ADM) capability dedicated to meet the needs of the DOD. The MCM ADM capabilities established by Nanotherapeutics will allow the DOD to more efficiently and expeditiously develop Medical Countermeasures (MCM) to protect and treat military populations against chemical, biological, radiological, and nuclear (CBRN) attacks and outbreaks of naturally occurring emerging and genetically engineered infectious diseases
ViewRay™ Inc., a medical device company, has appointed industry veteran Chris A. Raanes as president and CEO. Raanes joins ViewRay from Accuray Incorporated, where he served as executive vice president and chief operating officer. At ViewRay, he will be charged with driving the worldwide commercial growth of the ViewRay system, which provides a unique combination of simultaneous radiotherapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer.
SMART Biotechnologies -- New Subsidiary of UF Startup Xhale -- Appoints Thomas J. Bigger as President
SMART Biotechnologies, Inc., the newest subsidiary of the medical technology innovator, Xhale, Inc., has just appointed Mr. Thomas J. Bigger as its new president. Mr. Bigger comes to SMART with over 20 years of experience building shareholder value in pharmaceutical companies globally
UF startup Quick-Med Technologies, Inc., a life-sciences company that is developing innovative technologies for the healthcare and consumer markets, announced that Viridis BioPharma Pvt. Ltd. has begun selling and shipping Microfoam™ dressings to customers. Microfoam is the first advanced wound care dressing to utilize Quick-Med's proprietary non-leaching NIMBUS technology. Viridis received approval by the Food and Drug Administration of India in September 2011 to manufacture and market Microfoam wound dressings incorporating NIMBUS antimicrobial technology.
Applied Genetic Technologies Corp. (AGTC) bagged $37.5 million in a Series B financing that will let the company finish two Phase II trials with separate drug candidates, and see the firm through a pair of new, Phase I/II studies with other compounds in orphan eye diseases. Sue Washer, president and CEO of Gainesville, Fla.-based AGTC, noted that monoclonal antibodies took 25 years to ripen, and gene therapy is nearing the end of a similar timeline. Such is the road "for brand new, cutting-edge technologies to really come into their own," she said. "Everyone is very well convinced [that
The Alachua company based on technology developed at UF has secured $37.5 million in venture capital funding in what is believed to be the largest private venture deal ever for an area company.
It was a banner week in what has become a banner year in financing for area technology companies. Eight area companies have announced financing deals totaling more than $50 million this year. The University of Florida’s Innovation Hub business incubator reported that its tenant companies secured a combined $7.2 million in private investments in the 10 months through June 30. After years of venture capital deals trickling into the area, the money is starting to flow.
Prioria, which makes unmanned aerial vehicles for military and civilian surveillance, plans to create 40 new jobs over the next three years on top of the 30 it already has. The city of Gainesville is renovating the building abandoned when Gainesville Regional Utilities opened its new operations center on North Main Street. Prioria will lease it when construction is complete early next year.
Alachua-based AxoGen closed on nearly $21 million in financing to expand sales and development of products used in surgeries to repair peripheral nerve damage, the company announced late Tuesday. The financing comes from PDL BioPharma, based in Incline Village, Nev. PDL developed antibodies used to treat cancer and immunologic diseases and now invests in biotech companies and products.
Clinipace Worldwide announced Tuesday that it is acquiring a California contract research organization that will more than double the size of its workforce. The deal for Paragon Biomedical is the third acquisition Clinipace has made in the past 18 months. The combined company will employ more than 430 worldwide and is expected to generate revenues of $55 million this year.
A small medical startup in Newberry is one of two companies in the nation to win a grant from a science institute funded by NASA. The National Space Biomedical Research Institute awarded Enterade USA $100,000 to develop a drink that limits stomach problems from radiation exposure.
Alachua-based biotechnology company Pasteuria Bioscience is being acquired by Swiss agribusiness giant Syngenta in a deal worth up to $113 million, the companies announced Wednesday. Pasteuria Bioscience has been working with Syngenta since June 2011 to develop products to control plant-killing nematodes that cause an estimated $100 billion in crop damage worldwide each year.
Fast-growing startup graduates from Florida Innovation Hub at UF, moves to downtown Gainesville (UF News Bureau release)
Shadow Health Inc., a virtual education and training company based on University of Florida computer-programming technology, graduated from the Florida Innovation Hub at UF with an informal ceremony in the lobby.
Two UF startups, Prometheon Pharma and ReliOx Corp. are finalists for the Cade Prize. Out of more than 120 Florida inventors and entrepreneurs to apply, four remain standing in the chase for the third annual $50,000 Cade Museum Prize.
When we talk about doppler radar here at TV20, it's usually Bill Quinlan assessing current weather conditions. But smaller versions of doppler radar can be used for other purposes. And one of them assesses current medical conditions. The device can measure your heart rate and other signs--from a distance of several meters. CEO Tim Toppen and inventor Yan Yan of "Mind2Market" test out their vital signs monitor on TV20's David Snyder.
If something needs fixing, you put a patch on it. These days, that means fixing a medical condition. Patches are used to deliver medicine--but there's a problem. The skin is an effective barrier, permitting only small chemical compounds through. That means many medications can't be used in a patch. Until now. Stephen Hsu with Prometheon Pharma tells TV20's David Snyder how he made the breakthrough in the Innovation Technology interview.
A company that’s developing MRI-based technology to deliver radiation therapy to cancer patients has secured $10 million in new investment funding. Oakwood Village, Ohio-based ViewRay‘s $10.3 million fundraise comes from existing investors, according to a document filed with U.S. Securities and Exchange Commission.
Alachua-based biotechnology firm AxoGen Inc. is now a publicly traded company after completing its merger with LecTec Corp. The combined company is taking the name AxoGen Inc. and is initially trading on the Over-the-Counter Bulletin Board under LecTec’s symbol LECT but has filed with the Financial Industry Regulatory Authority to change the symbol to AXGN, according to a news release. The companies announced their intention to merge in June in a $12.5 million stock deal.
Syngenta Lawn & Garden (L&G) announced today that it has entered into an agreement with Pasteuria Bioscience Inc., a U.S.-based biotechnology company. Under the terms of the agreement, Syngenta’s Turf & Landscape division will have exclusive licensing and distribution rights in global turf markets to Pasteuria Biosciences' existing and future nematicide product lines based on the naturally occurring biological agent Pasteuria.
Clinipace Worldwide, a digital contract research organization that was recently named to the Inc. 500 list, has closed a $15 million Series C round. The round was led by Morgan Stanley Expansion Capital of San Francisco, with participation from existing investors Hatteras Venture Partners of Durham and Brook Private Equity Advisors of Boston. Hatteras was the lead investor in Clinipace’s Series B round in 2007, when it raised $2.5 million.
Rapidly expanding Clinipace Worldwide has raised an additional $10.5 million to keep its momentum going. The Morrisville company, a contract research organization that helps pharmaceutical companies test experimental drugs, is looking to continue hiring internally as well as make more acquisitions. In May Clinipace acquired a 65-employee Swiss firm -- its third purchase in an 18-month span, and by far its largest in terms of number of employees.
A company that’s developing MRI-based technology to deliver radiation therapy to cancer patients has secured $10 million in new investment funding. Oakwood Village, Ohio-based ViewRay‘s $10.3 million fundraise comes from existing investors, according to a document filed with U.S. Securities and Exchange Commission. Investors listed in the document include Kearny Venture Partners, OrbiMed Advisors, Fidelity Bioscience, Aisling Capital and Siemens. All of those investors participated in a $20 million series C round that ViewRay announced in August 2010.
Alachua, FL – Optima Neuroscience, Inc. (Optima) and Tucker-Davis Technologies, Inc. (TDT) today announced that they have entered into a definitive agreement under which TDT will acquire Optima, a privately held medical device company focused on the development of clinical brain monitoring technologies pioneered at the University of Florida. The transaction was unanimously approved by the directors of both companies.
Pasteuria: Dave Duncan is on the cusp of another ag phenomenon, a solution to nematodes (Gainesville Sun)
Alachua — Dave Duncan saw in Pasteuria Bioscience the same potential to become a worldwide, $1 billion-plus agricultural phenomenon as Monsanto's Roundup. He should know. Duncan was one of the early developers of Roundup in the 1970s, and later ran Monsanto's specialty crop division in St. Louis.
(From Wired.com article): Fighting Germs Like a Shark Unlike the skin of whales and manatees, shark skin doesn’t pick up algae or barnacles. This seems to be due to little scales called “dermal denticles.” Sharklet is an engineered surface that, through pattern alone, inhibits bacterial growth. The company, Sharklet Technologies, Inc., sells adhesive-backed films for covering surfaces and manufactures the pattern into medical devices like urinary catheters.
Lifehacker listed Grooveshark among its favorite streaming-music services. Readers also named Grooveshark their favorite service last year http://lifehacker.com/5483355/best-music-streaming-service-grooveshark
Pasteuria Bioscience Inc. has partnered with Syngenta, the largest agri-business company in the world, to develop nematode control products for agricultural and specialty crops. The partnership will lead to the worldwide commercialization of Pasteuria-based products, Pasteuria Bioscience CEO David Duncan said in a news release Tuesday. “This is bigger than anything we could have imagined,” Duncan said.
Grooveshark founder says Gainesville location helped company succeed (Washington Post and Bloomberg news video)
Sam Tarantino, chief executive officer of Grooveshark talks about the company's business model, competition and music licensing issues. Locating in Gainesville, with low costs and a large talent pool, helped Grooveshark succeed, Tarantino says.
Alachua-based biotechnology company AxoGen Inc. plans to go public through a merger with Texas-based LecTec Corp. in a stock deal worth at least $12.5 million. AxoGen makes three products to repair peripheral nerve damage. The deal would allow the company to expand development, marketing and sales in the U.S. and internationally, CEO Karen Zaderej said in a news release.
Bio-based chemicals developer Myriant Corp., known until recently as Myriant Technologies LLC, has filed for an initial public offering that could bring in up to $125 million, according to federal documents filed by the company.
Florida Sustainables: Creating a plastic alternative; Cade Prize winner develops ‘green’ polymer that is stronger (Gainesville Sun)
The winner of the 2011 Cade Prize for Innovation hopes to replace plastic grocery bags, cups, milk jugs and other plastics with their degradable plastics and has had talks with major companies such as Wal-Mart, PepsiCo and Procter & Gamble. Florida Sustainables has licensed a polymer invented by University of Florida graduate student Ryan Martin and associate chemistry professor Stephen Miller, the company's technical team who accepted the award May 12.
A startup company with a biodegradable plastic invented at the University of Florida was the winner of the second $50,000 Cade Prize for Innovation. "This is incredible. I feel like I'm on ‘American Idol,' " Ryan Martin said in accepting the award. Martin is a UF chemistry student who pitched the company with professor Steve Miller to a panel of judges that included Karl Tryggvason, an expert in medical chemistry who is a member of the Nobel Prize selection committee. The award was created by the Cade Museum Foundation to help strengthen a culture of innovation and create jobs in Gainesvi
HyGreen, Inc. announced today that St. Jude Children’s Research Hospital, an international leader in the research and treatment of children with cancer and other catastrophic diseases, has implemented the HyGreen® Hand Hygiene Reminder System in its Bone Marrow Transplant Unit.
Former University of Florida President Marshall Criser Jr. has been elected chairman of the board of the Gainesville startup company Sestar Technologies. Sestar is commercializing several green products licensed from University of Florida research. Its Sgen polymer-based photovoltaic coatings can be used to make solar-powered camouflage military tents or artificial turf. Its SurfPlasma coating senses contamination and self-sterilizes medical equipment. Its biodegradable plastic for grocery bags is a final-four contestant for the $50,000 Cade Prize for Innovation.
Littlebanc Advisors, LLC Boca Raton on April 14 announced the completion of a $3 million Series A Preferred financing for Apollidon, Inc. The round was funded by Sopris Capital Associates, a venture capital firm that partners and provides funding to early and growth stage companies. The $3 million capital raise will allow Apollidon to accelerate development of its education marketing programs for its network of public universities dedicated to creating and implementing high quality and economical distance learning programs and services.
From NBCMiami.com: After using Hygreen from September to March, the hospital-acquired infection rate dropped 89 percent. They used to get around five cases every three months, now they get less than one. As the mother of a young cancer patient, it’s one less thing Barbara Padilla has to worry about. “It makes me feel good this hospital takes a little bit more initiative making sure they’re clean, sanitary.”
DENVER - Sharklet Technologies, Inc. today announced that it has been awarded a $1.2 million Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) / National Institute of Diabetes and Digestive and Kidney Diseases* to continue its development of a urinary Foley catheter with the Sharklet micro-pattern that inhibits bacterial growth on the surface of the catheter.
The grant will help Sinmat develop low-cost, scalable manufacturing of surface-engineered super-hard substrates for next-generation electronic and photonic devices(Gainesville Sun).
Xhale Innovations’HyGreen Hand Hygiene System was installed at Jesse Brown Veterans Affairs Medical Center (JBVAMC) in Chicago, IL. This is the first installation of HyGreen into the VA system nationally(CNBC).
The UF startup has perfected realizable, breakthrough QLED display technology and is commercializing the technology for mass production (CBS MoneyWatch)
Sharklet: Featured by New York Times Columnist David Pogue on Special CBS News Nova Series, “Making Stuff Smarter”
The New York Times columnist explores how shark skin could help save lives and interviews Sharklet inventor Dr. Anthony Brennan of UF.
Optima Neuroscience, Inc., a privately held medical-device company focused on the development of brain-monitoring technologies, announced in a press release that it had closed a Series A financing round. The funding, in combination with strong grant support from the National Institute of Neurological Disorders and Stroke, will allow the company to increase sales and marketing efforts for its software product, IdentEvent®, as well as to continue developing an innovative line of hardware-based brain monitors.
Applied Genetic Technologies Corp., a privately held company, received two $1 million grants from the Food and Drug Administration to develop therapies for genetic causes of blindness and emphysema, the company said in a press release.
EVEN AS doctors have learned more about brain trauma, the definition of a concussion remains frustratingly vague. The injury is diagnosed through a mishmash of symptoms, some of which may or not be present in any particular case. Bone breaks have X-rays and muscle tears have MRIs, but no form of medical imaging has yet been able to quickly and reliably confirm a concussion diagnosis. But a number of promising tests are in the medical pipeline ... Last month the U.S. Army, in partnership with the Alachua, Fla.--based company Banyan Biomarkers, announced a potential breakthrough in the developme
Banyan Biomarkers Inc. Awarded $26.3 Million Contract for Tramautic Brain Injury Test; Featured in Wall Street Journal
Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), received a $26.3 Million contract to develop a diagnostic test for TBI. Banyan’s good news was featured in the national media, including this Wall Street Journal story.
Banyan Biomarkers Inc. Awarded $26.3 Million Contract for Tramautic Brain Injury Test; Featured in USA Today
Banyan Biomarkers, Inc., the leader in developing in vitro diagnostic products to detect traumatic brain injury (TBI), received a $26.3 Million contract to develop a diagnostic test for TBI, according to a press release from the company. Banyan’s good news was featured in the national media, including this USA Today story.
UF startup AGTC was featured in a story in The Oregonian about a 6-year-old girl receiving gene therapy for vision loss.